Терминология, диагностика, варианты течения и терапии при системной красной волчанке неполной
https://doi.org/10.30629/0023-2149-2022-100-9-10-447-455
Аннотация
В обзоре речь пойдет о «преволчанке» — состоянии, которое не классифицируется в соответствии с современными критериями как «определенная» системная красная волчанка, но имеет неполное количество признаков, характерных для данной болезни. Цель обзора – ознакомить читателей с диагностикой, терминологией, вариантами течения и целесообразностью терапии неполной системной красной волчанки.
Ключевые слова
системная красная волчанка,
неполная системная красная волчанка,
классификационные критерии,
варианты течения,
лечение
При поддержке: Исследование не имело спонсорской поддержки
Об авторах
Т. А. Панафидина
ФГБУН Научно-исследовательский институт ревматологии им. В.А. Насоновой
Россия
Россия
Панафидина Татьяна Александровна — кандидат медицинских наук, старший научный сотрудник лаборатории системной красной волчанки.
115522, Москва
Т. В. Попкова
ФГБУН Научно-исследовательский институт ревматологии им. В.А. Насоновой
Россия
Россия
Попкова Татьяна Валентиновна — доктор медицинских наук, руководитель отдела системных ревматических заболеваний, заведующая лабораторией системной красной волчанки.
115522, Москва
А. М. Лила
ФГБУН Научно-исследовательский институт ревматологии им. В.А. Насоновой; ФГБОУ ДПО Российская медицинская академия непрерывного профессионального образования Минздрава России
Россия
Россия
Лила Александр Михайлович — доктор медицинских наук, профессор, член-корр. РАН, директор ФГБНУ «НИИР им. В.А. Насоновой», заведующий кафедрой ревматологии ФГБОУ ДПО.
115522, 125993, Москва
Список литературы
1. Gatto M., Saccon F., Zen M., Iaccarino L., Doria A. Preclinical and early systemic lupus erythematosus. Best. Pract. Res. Clin. Rheumatol. 2019;33(4):101422. DOI: 10.1016/j.berh.2019.06.004
2. Ревматология. Клинические рекомендации. Под ред. Насонова Е.Л. М., ГЭОТАР-Медиа, 2010;429–81.
3. Davidson A., Diamond B. Autoimmune diseases. N. Engl. J. Med. 2001;345(5):340–50. DOI: 10.1056/NEJM200108023450506
4. Lambers W.M., Westra J., de Leeuw K. et al. Incomplete systemic lupus erythematosus – what remains after application of ACR and SLICC criteria? Arthritis Care Res. 2020;72(5):607–614. DOI: 10.1002/acr.23894
5. Насонов Е.Л. и соавт. Проблемы ранней диагностики системной красной волчанки в период пандемии COVID-19. Научно-практическая ревматология. 2021;59(2):119–128. DOI: 10.47360/1995-4484-2021-119-128
6. Aringer M., Costenbader K., Daikh D. et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann. Rheum. Dis. 2019;78(9):1151–9. DOI: 10.1136/annrheumdis-2018-214819
7. Соловьев С.К., Асеева Е.А., Попкова Т.В. и др. Системная красная волчанка: новые горизонты диагностики и терапии. Научнопрактическая ревматология. 2020;58(1):5–14. [Solovyev S.K., Aseeva E.A., Popkova T.V. et al. Systemic lupus erythematosus: new horizons for diagnosis and therapy. Rheumatology Science and Practice. 2020;58(1):5–14. (In Russian)]. DOI: 10.14412/1995-4484-2020-5-14
8. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. DOI: 10.1002/art.1780400928
9. Petri M. et al. Derivation and Validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheum. 2012;64(8):2677–86. DOI: 10.1002/art.34473
10. Doria A., Zen M., Canova M. et al. SLE diagnosis and treatment: when early is early. Autoimmun. Rev. 2010;10:55–60. DOI: 10.1016/j.autrev.2010.08.014
11. Agmon-Levin N., Damoiseaux J., Kallenberg C. et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann. Rheum. Dis. 2014;73:17–23. DOI: 10.1136/annrheumdis-2013-203863
12. Pisetsky D.S. Antinuclear Antibody Testing — Misunderstood or Misbegotten? Nat. Rev. Rheumatol. 2017;13(8):495–502. DOI: 10.1038/nrrheum.2017.74
13. Mosca M., Costenbader K.H., Johnson S.R., Hoyer B.F. et al. How do patients with newly diagnosed systemic lupus erythematosus present? A multicenter cohort of early systemic lupus erythematosus to inform the development of new classification criteria. Arthritis Rheumatol. 2018;71(1):91–98. DOI: 10.1002/art.40674
14. Pisetsky D.S., Bossuyt X., Meroni P.L. ANA as an entry criterion for the classification of SLE. Autoimmun. Rev. 2019;18(12):102400. DOI: 10.1016/j.autrev.2019.102400
15. Leuchten N., Bertsias G., Smolen J. et al. Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data. Arthritis Care Res. (Hoboken). 2018;70(3):428–438. DOI: 10.1002/acr.23292
16. Tan E.M., Eltkamp T.E., Smolen J.S. et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum. 1997;40(9): 1601–11. DOI: 10.1002/art.1780400909
17. Wandstrat A., Carr-Johnson F., Branch V. et al. Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus. J. Autoimmun. 2006;27:153–60. DOI: 10.1016/j.jaut.2006.09.001
18. Adamichou C. et al. In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify nonoverlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment Ann. Rheum. Dis. 2020;79:232–241. DOI: 10.1136/annrheumdis-2019-216155
19. Lambers W.M., Westra J., de Leeuw K. et al. Incomplete systemic lupus erythematosus — what remains after application of ACR and SLICC criteria? Arthritis Care Res. 2020;72(5):607–614. DOI: 10.1002/acr.23894
20. Chen Z., Li M.T., Xu D. et al. Organ damage in patients with incomplete lupus syndromes: From a Сhinese academic center. Clin. Rheumatol. 2015;34(8):1383–1389. DOI: 10.1007/s10067-015-2884-3
21. Olsen N.J., McAloose C., Carter J. et al. Clinical and immunologic profiles in incomplete lupus erythematosus and improvement with hydroxychloroquine treatment. Autoimmune Dis. 2016;2016: 8791629. DOI: 10.1155/2016/8791629
22. Arbuckle M.R., McClain M.T., Rubertone M.V. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 2003;349:1526–33. DOI: 10.1056/NEJMoa021933
23. Eriksson C., Kokkonen H., Johansson M. et al. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis. Res. Ther. 2011;13:R30. DOI: 10.1186/ar3258
24. Scofield R.H. Autoantibodies as Predictors of Disease. Lancet. 2004;363(9420):1544–6. DOI: 10.1016/S0140-6736(04)16154-0
25. Heidenreich U., Mayer G., Herold M. et al. Sensitivity and specificity of autoantibody tests in the differential diagnosis of lupus nephritis. Lupus. 2009;18:1276–80. DOI: 10.1177/0961203309345753
26. Gensous N., Marti A., Barnetche Tet. et al. Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review. Arthritis Res. Ther. 2017;19:238. DOI: 10.1186/s13075-017-1442-6
27. Li T., Prokopec S.D., Morrison S. et al. Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosus. Rheumatology (Oxford). 2015;54:449–57. DOI: 10.1093/rheumatology/keu326
28. Orbai A.M., Truedsson L., Sturfelt G. et al. Anti-C1q antibodies in systemic lupus erythematosus. Lupus. 2015;24:42–9. DOI: 10.1177/0961203314547791
29. Mok C.C., Ho LY., Leung H.W. et al. Performance of anti-C1q, antinucleosome, and anti-dsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus. Transl. Res. 2010;156:320–5. DOI: 10.1016/j.trsl.2010.07.009
30. Yuan M., Tan Y., Pang Y. et al. Anti-pentraxin 3 auto-antibodies might be protective in lupus nephritis: a large cohort study. Ren Fail. 2017;39:465–73. DOI: 10.1080/0886022X.2017.1308258
31. Al Daabil M., Massarotti E.M., Fine A. et al. Development of SLE among “potential SLE” patients seen in consultation: longterm follow-up. Int. J. Clin. Pract. 2014;68:1508–13. DOI: 10.1111/ijcp.12466
32. Mosca M., Costenbader K.H., Johnson S.R., Touma Z. et al. Brief Report: How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria. Arthritis Rheumatol. 2019;71(1):91–98. DOI: 10.1002/art.40674
33. Adamichou C., Genitsaridi I., Nikolopoulos D., Boumpas D.T., Bertsias G.K. et al. Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus. Ann. Rheum. Dis. 2021;0:1–9. DOI:10.1136/annrheumdis-2020-219069
34. Oglesby A., Korves C., Laliberte F. et al. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes. Appl. Health Econ. Health Policy. 2014;12:179–90. DOI: 10.1007/s40258-014-0085-x
35. James J.A., Kim-Howard X.R., Bruner B.F. et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus. 2007;16:401–9. DOI: 10.1177/0961203307078579
36. Gerlag D., Safy M., Maijer K., Tak P.P. et al. OP0182 Prevention of Rheumatoid Arthritis by B Cell Directed Therapy in The Earliest Phase of The Disease: The Prairi Study. Annals of the Rheumatic Diseases. 2016;75(2):125–126. DOI: 10.1136/annrheumdis-2016-eular.6042
37. Olsen N.J., James J.A., Arriens C., Karp D.R. et al. Study of AntiMalarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial. Trials. 2018:19(1);694. DOI: 10.1186/s13063-018-3076-7
38. Попкова Т.В., Панафидина Т.А., Соловьев С.К. По материалам обновленных рекомендаций Европейской антиревматической лиги (EULAR) по лечению системной красной волчанки — 2019: дискуссионные вопросы и комментарии. Научно-практическая ревматология. 2019;57(5):496–510. DOI: 10.14412/1995-4484-2019-496-510
39. Durcan L., Petri M. Immunomodulators in SLE: clinical evidence and immunologic actions. J. Autoimmun. 2016;74:73–84. DOI: 10.1016/j.jaut.2016.06.010
40. Ruiz-Irastorza G., Cuadrado M.J., Ruiz-Arruza I. et al. Evidencebased recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th international congress on antiphospholipid antibodies. Lupus. 2011;20:206–18. DOI: 10.1177/0961203310395803
41. Arnaud L., Mathian A., Devilliers H. et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun. Rev. 2015;14:192–200. DOI: 10.1016/j.autrev.2014.10.019
42. Pengo V., Ruffatti A., Legnani C. et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J. Thromb. Haemost. 2010;8:237–42. DOI: 10.1111/j.1538-7836.2009.03674.x
43. Mok C.C., Penn H.J., Chan K.L. et al. Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: a longitudinal cohort analysis. Arthritis Care Res. (Hoboken). 2016;68:1295–302. DOI: 10.1002/acr.22837
44. Costedoat-Chalumeau N., Amoura Z., Hulot J.S. et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54:3284.–90. DOI: 10.1002/art.22156
45. Fanouriakis A., Kostopoulou M., Alunno A. et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis. 2019;78(6):736–45. DOI: 10.1136/annrheumdis-2019-215089
46. Marmor M.F., Kellner U., Lai T.Y. et al. American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123:1386–94. DOI: 10.1016/j.ophtha.2016.01.058
47. Adorini L., Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat. Clin. Pract. Rheumatol. 2008;4(8):404–12. DOI: 10.1038/ncprheum0855
48. Amital H., Szekanecz Z., Szücs G., Dankó K., Nagy E., Csépány T. et al. Serum concentrations of 25-OH Vitamin D in SLE patients are inversely related to disease activity—is it time to routinely supplement SLE patients with vitamin D? Ann. Rheum. Dis. 2010;69(6):1155–7. DOI: 10.1136/ard.2009.120329
49. Kreuter A., Gambichler T., Breuckmann F. et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J. Am. Acad. Dermatol. 2004;51(3):407–10. DOI: 10.1016/j.jaad.2004.01.044
50. Kuhn A., Gensch K., Haust M. et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: A multicenter, randomized, double-blind, vehicle-controlled trial. J. Am. Acad. Dermatol. 2011;65(1):54–64,64.e1–2. DOI: 10.1016/j.jaad.2010.03.037
51. Chaturvedi S., Arnold D.M., McCrae K.R. Splenectomy for immune thrombocytopenia: down but not out. Blood. 2018;131(11):1172–82. DOI: 10.1182/blood-2017-09-742353
52. You Y.N., Tefferi A., Nagorney D.M. Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus. Ann. Surg. 2004;240:286–92. DOI: 10.1097/01.sla.0000133182.92780.9c
53. Jung J.-H., Soh M.-S., Ahn Y.-H. et al. Thrombocytopenia in systemic lupus erythematosus: clinical manifestations, treatment, and prognosis in 230 patients. Medicine (Baltimore). 2016;95(6):e2818. DOI: 10.1097/MD.0000000000002818
54. Olfat M., Silverman E.D., Levy D.M. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus. Lupus. 2015;24(9):966–72. DOI: 10.1177/0961203315578764
55. Chugh S., Darvish-Kazem S., Lim W. et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and metaanalysis. Lancet Haematol. 2015;2(2):75– 81. DOI: 10.1016/S2352-3026(15)00003-4
56. Serris A., Amoura Z., Canoui-Poitrine F. et al. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immunecytopenias: a multicenter retrospective cohort study of 71 adults. Am. J. Hematol. 2018;93(3):424–9. DOI: 10.1002/ajh.24999
57. Toro-Domínguez D., Martorell-Marugan J., Goldman D. et al. Stratification of systemic lupus erythematosus patients into three groups of disease activity progression according to longitudinal gene expression. Arthritis Rheum. 2018;70(12):2025–35. DOI: 10.1002/art.40653
58. Li Q.Z., Zhou J., Lian Y., Olsen N.J. et al. Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes. Clin. Exp. Immunol. 2010;159(3):281– 291. DOI: 10.1111/j.1365-2249.2009.04057.x
59. Pejchinovski M., Siwy J., Mullen W. et al. Urine peptidomic biomarkers for diagnosis of patients with systematic lupus erythematosus. Lupus. 2018;27(1):6–16. DOI: 10.1177/0961203317707827
60. Cardenas-Gonzalez M., Srivastava A., Pavkovic M. et al. Identification, confirmation, and replication of novel urinary microRNA biomarkers in lupus nephritis and diabetic nephropathy. Clin. Chem. 2017;63(9):1515–26. DOI: 10.1373/clinchem.2017.274175
61. La’ulu S.L., Suh-Lailam B.B., Davis K.W. et al. Comparative analysis of neutrophil gelatinase-associated lipocalin and other laboratory markers for lupus nephritis: a cross-sectional investigation. Ann. Clin. Biochem. 2017;54(2):240–5. DOI: 10.1177/0004563216651888
62. Nicolaou O., Kousios A., Hadjisavvas A. et al. Biomarkers of systemic lupus erythematosus identified using mass spectrometrybased proteomics: a systematic review. J. Cell. Mol. Med. 2017;21: 993–1012. DOI: 10.1111/jcmm.13031
63. Lu R., Munroe M.E., Guthridge J.M., James J.A. et al. Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J. Autoimmunity. 2016;74:182–193. DOI: 10.1016/j.jaut.2016.06.001
Рецензия
Для цитирования:
Панафидина Т.А., Попкова Т.В., Лила А.М. Терминология, диагностика, варианты течения и терапии при системной красной волчанке неполной. Клиническая медицина. 2022;100(9-10):447-455. https://doi.org/10.30629/0023-2149-2022-100-9-10-447-455
For citation:
Panafidina T.A., Popkova T.V., Lila A.M. Incomplete systemic lupus erythematosus: terminology, diagnosis, course and therapy. Clinical Medicine (Russian Journal). 2022;100(9-10):447-455. (In Russ.) https://doi.org/10.30629/0023-2149-2022-100-9-10-447-455
Просмотров:
659
Послать статью по эл. почте 